by jtcir-auto | Mar 20, 2025 | Press Releases
TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical,...
by jtcir-auto | Mar 13, 2025 | Press Releases
No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to be treated in the Phase 2a Clinical Efficacy Study on March 14, 2025 at...
by jtcir-auto | Mar 13, 2025 | Press Releases
No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to be treated in the Phase 2a Clinical Efficacy Study on March 14, 2025 at...
by jtcir-auto | Dec 23, 2024 | Press Releases
Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward New corporate presentation outlining...
by jtcir-auto | Nov 12, 2024 | Press Releases
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI)...
by jtcir-auto | Nov 12, 2024 | Press Releases
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI)...